SBIR Phase I: Development and Characterization of Bio-inert UNCD films for Implantable Devices to Eliminate Blood Clotting

SBIR 第一阶段：用于消除血液凝固的植入装置的生物惰性 UNCD 薄膜的开发和表征

• 批准号: 0912855
• 负责人: John Carlisle
• 金额: $ 9.99万
• 依托单位: ADVANCED DIAMOND TECHNOLOGIES
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0912855&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; Characterization; Bio

This Small Business Innovation Research Phase I project will investigate UNCD®, a nanocrystalline from of smooth, thin diamond, as an anti-thrombotic coating for implantable medical devices. One of the largest problem with implantable circulatory assist devices such as artificial hearts and vascular assist devices (VADs) is the need to treat patients with anticoagulants to avoid blood clots within the devices and to avoid heart attack, stroke, and death that may occur if the anticoagulation dosage is not right. Previous work on diamond and diamond-like carbon (DLC) has demonstrated reduced interactivity between the coating and human blood clotting factors. The use of UNCD however, with its overall biochemical and electrochemical inertness, extreme durability to wear, and very low surface roughness, will extend the advantages previously demonstrated with other carbon materials. The broader impacts of this research are the potential reduction or elimination of anticoagulants for patients with implanted medical devices, making a much larger patient population eligible for advanced devices such as heart pumps, and enabling the use of these devices for new applications. UNCD coatings on the blood contacting surfaces of these and similar devices has the potential to eliminate the need for anticoagulation or to reduce it to so low a dose that the risk of fatal bleeding can be eliminated. The reduction in prescription costs alone could pay for this investment many times over. Fundamental work will also shed light on the effects of dynamic blood flow, variations in surface chemistry and morphology on the thrombus/clot formation.This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

这个小企业创新研究第一阶段项目将研究UNCD®，一种光滑，薄金刚石的纳米晶，作为植入式医疗设备的抗血栓涂层。植入式循环辅助装置如人工心脏和血管辅助装置（VAD）的最大问题之一是需要用抗凝剂治疗患者以避免装置内的血凝块，并避免如果抗凝剂剂量不正确可能发生的心脏病发作、中风和死亡。以前对金刚石和类金刚石碳（DLC）的研究表明，涂层与人体凝血因子之间的相互作用降低。然而，UNCD的使用，由于其整体的生物化学和电化学惰性，极高的耐磨性和极低的表面粗糙度，将扩展先前用其他碳材料证明的优点。这项研究的更广泛影响是潜在减少或消除植入医疗器械的患者的抗凝剂，使更多的患者人群有资格使用先进的设备，如心脏泵，并使这些设备能够用于新的应用。这些和类似设备的血液接触表面上的UNCD涂层有可能消除抗凝剂的需要或将其减少到如此低的剂量，从而消除致命出血的风险。 单是减少处方费用就可以支付这项投资的许多倍。 基础工作也将阐明动态血流的影响，表面化学和形态的变化对血栓/凝块形成。该奖项是根据2009年美国复苏和再投资法案（公法111-5）资助。